S&P 500
5.018,39 -17,30 (-0,34%) Nasdaq
15.605,48 -52,34 (-0,33%) NIKKEI 225
38.274,05 -131,61 (-0,34%) Dólar/Euro
1,0719 +0,0001 (+0,01%) Petróleo Brent
83,43 -0,01 (-0,01%) Bitcoin EUR
54.489,47 -2.250,47 (-3,97%)
Spero Therapeutics, Inc. (SPRO)
Spero Therapeutics, Inc.
675 Massachusetts Avenue
14th Floor
Cambridge, MA 02139
United States
857 242 1600
https://sperotherapeutics.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 46
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Ankit Mahadevia M.D., MBA | Co-Founder & Chairman of the Board | 1,39M | N/A | 1981 |
| Mr. Satyavrat Shukla C.F.A. | President, CEO & Director | 1,12M | N/A | 1973 |
| Mr. Timothy Keutzer | Chief Operating Officer | 938,57k | N/A | 1968 |
| Ms. Esther P. Rajavelu | CFO, Chief Business Officer & Treasurer | N/A | N/A | 1979 |
| Mr. James P. Brady | Chief Human Resource Officer | N/A | N/A | N/A |
| Dr. Kamal Hamed M.B.A., M.D., M.P.H. | Chief Medical Officer | N/A | N/A | 1961 |
Descripción
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Gobierno corporativo
El ISS Governance QualityScore de Spero Therapeutics, Inc., a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.
